G. Rustin

发表

Use of CA 125 in follow-up of ovarian cancer

M. Tuxen, G. Rustin, 1996, The Lancet.

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations.

M. Hall, G. Rustin, T. I. Goonewardene, 2007, The Lancet. Oncology.

Patient Support Groups Identifying Clinical Equipoise in UK Gynaecological Oncology Surgeons as the Basis for Trials in Ultraradical Surgery for Advanced Ovarian Cancer

S. Kehoe, C. Fotopoulou, C. Founta, 2015, International Journal of Gynecologic Cancer.

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

R. Bast, L. Burke, S. Horning, 2007, Gynecologic oncology.

Using Serum CA125 to Assess the Activity of Potential Cytostatic Agents in Ovarian Cancer

D. Kornbrot, S. M. Crawford, M. Hall, 2014, International Journal of Gynecologic Cancer.

Can we now agree to use the same definition to measure response according to CA-125?

G. Rustin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of good-risk, stage II, non-seminomatous testis cancer

C. Boshoff, E. Newlands, T. Oliver, 1994, The Lancet.

Early versus delayed treatment of relapsed ovarian cancer

C. Griffin, W. Qian, A. Swart, 2011, The Lancet.

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Corneel Coens, Alan Lamont, Gordon C Jayson, 2010, The Lancet.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

I. Tannock, M. Parmar, R. Souhami, 2002, The Lancet.

Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment

E. Berns, D. Lambrechts, F. Amant, 2014, International Journal of Gynecologic Cancer.

Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment

A. D'Amico, R. Bast, R. Schilsky, 2004, Clinical Cancer Research.

Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors

D. Collins, A. Padhani, M. Leach, 2007, Journal of magnetic resonance imaging : JMRI.

Targeted anti-vascular therapies for ovarian cancer: current evidence

J Ledermann, M. Gore, J. Ledermann, 2013, British Journal of Cancer.

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

E. Newlands, G. Rustin, K. Bagshawe, 1991, The Lancet.

Vascular damaging agents.

G. Rustin, G. Rustin, D. Patterson, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Vascular disrupting agents: a new class of drug in cancer therapy.

G. Rustin, A. Gaya, G. Rustin, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

G. Jayson, M. Sawyer, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Epithelial ovarian cancer: a review of current management.

G. Rustin, P. Nathan, G. Rustin, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2010, British Journal of Cancer.

Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.

G. Rustin, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.